Item 7.01 Regulation FD Disclosure.

On March 26, 2022, Krystal Biotech, Inc. (the "Company") presented more detailed results from the GEM-3 Phase 3 study of beremagene geperpavec (B-VEC), an investigational, topical gene therapy, for the treatment of dystrophic epidermolysis bullosa (DEB), at the 2022 American Academy of Dermatology ("AAD") Annual Meeting in Boston, Massachusetts. In addition, the Company hosted an investor conference call at 8:00 a.m. ET on March 28, 2022 to discuss the more detailed results from the GEM-3 Phase 3 study. A copy of the slide presentation used on the investor conference call, which includes the slides presented at the AAD meeting, is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The slide presentation is also available on the "Investors" section of the Company's website at www.krystalbio.com.

This information in this Item 7.01 of this Current Report on Form 8-K and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit
  No.       Description

99.1          Slide Presentation for Investor Conference Call

104         Cover Page Interactive Data file (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses